CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 14 enrolled / 14 target
Drug / intervention
BI 1584862 +1 moredrug
Likely dose
BI 1584862 240 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06041438
NCT06041438Phase 1CompletedUpdate Overdue (0.4/mo)Completion was 31mo ago

Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1584862 in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Design Study)

Boehringer Ingelheim·interventional·Posted Sep 18, 2023·Updated Jun 3, 2026

In Brief

A Phase 1 clinical trial evaluating BI 1584862 and Itraconazole for Healthy. Completed, enrolled 14 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

The main objective of this trial is to investigate the effect on the exposure of BI 1584862 in plasma when given as single dose together with multiple doses of itraconazole (Test, T) as compared to BI 1584862 when given alone as oral single dose (Reference, R).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedSep 18, 2023
Enrollment StartSep 29, 2023
Primary CompletionNov 10, 2023
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 2.8 years ago

Arms & Interventions

BI 1584862 (R), then BI 1584862 + itraconazole (T)experimental

Reference treatment (R): healthy male subjects were administered one single dose of BI 1584862 as tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h). Test treatment (T): healthy male subjects were administered one single dose of BI 1584862 as tablets orally with 240 mL of water after an overnight fast of at least 10 h. Additionally, subjects were administered one daily dose of 200 milligram (mg) itraconazole as an oral solution after an overnight fast of at least 9 h for several consecutive days. The two administrations of BI 1584862 were separated by a washout period.

Drug: BI 1584862Drug: Itraconazole

Interventions

BI 1584862drug

One dose with 240 mL of water after an overnight fast of at least 10 h

Itraconazoledrug

200 mg daily after an overnight fast of at least 9 h for several consecutive days